ATXI News and Press, Avenue Therapeutics Inc. From 04/24/24

2024-04-24 07:58:30 ET More on Avenue Therapeutics Avenue Therapeutics granted extension for Nasdaq compliance Seeking Alpha’s Quant Rating on Avenue Therapeutics Historical earnings data for Avenue Therapeutics Financial information for Avenue Therape...

MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced th...

MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced th...

2024-03-19 06:53:18 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avenue Therapeutics (NASDAQ: ATXI ) just reported results for the fourth quarter of 2023. Avenue Therapeutics reported earnings per share of 56 cents. This was above the a...

2024-03-18 16:46:33 ET More on Avenue Therapeutics Avenue Therapeutics granted extension for Nasdaq compliance Avenue Therapeutics signs warrant exercise transactions for $5.0M in proceeds Seeking Alpha’s Quant Rating on Avenue Therapeutics Historical ...

- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - - Presented positive BAER-101 preclinical data at American Epilepsy Society (AES) and American Society for Experimental Neurotherapeuti...

2024-03-15 08:53:49 ET More on Avenue Therapeutics Avenue Therapeutics signs warrant exercise transactions for $5.0M in proceeds Seeking Alpha’s Quant Rating on Avenue Therapeutics Historical earnings data for Avenue Therapeutics Financial information ...

MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced th...

BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure drug development with high predictability of response in humans MIAMI, March 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Na...

2024-01-24 16:22:17 ET More on Avenue Therapeutics Avenue Therapeutics signs warrant exercise transactions for $5.0M in proceeds Avenue Therapeutics GAAP EPS of $0.06 beats by $0.32 Seeking Alpha’s Quant Rating on Avenue Therapeutics Historical earning...